Breaking News

Dr. Park Taps Thermo Fisher to Provide Bioreactors & Consumables for New Facility

The new facility has integrated and set up several solutions from Thermo Fisher’s portfolio.

Author Image

By: Charlie Sternberg

Associate Editor

Dr. Park, an emerging viral vector contract development and manufacturing organization (CDMO) based in South Korea, has selected Thermo Fisher Scientific Inc. to provide advanced bioreactors and consumables for its newest facility. Dr. Park specializes in Adeno-associated virus-based (AAV-based) viral vector production. The company’s new Phase 1 facility, which was inaugurated on August 5, 2025, is designed to achieve cGMP certification in 2026 and expand access to cell and gene therapies glo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters